Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
Journal of Infection · 2023
DOI: 10.1016/j.jinf.2023.01.018 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Infection, 2023. Verfasst von Chris A Gentry und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Oklahoma City Veterans Affairs Health Care System, 921 Northeast 13th Street (119), Oklahoma City, OK 73104, USA. Electronic addres…. Hauptthemen laut MEDLINE: COVID-19, Veterans. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVES: Molnupiravir and nirmatrelvir/ritonavir each became available in the United States (US) through the Food and Drug Administration (FDA) emergency use authorization (EUA) in December 2021 after their respective initial prospective randomized controlled trials demonstrated efficacy for patients with mild-to-moderate SARS-CoV-2 active infection considered to be at high risk for progression of disease and hospitalization. Although sufficiently powered for this wide group, the mean age for patients in these studies was only 43 and 46 years of age, respectively. We sought to compare outcomes of US Veterans 65 years and older who received either of these oral antivirals to those who did not receive oral antivirals for mild-to-moderate SARS-CoV-2 active infection. METHODS: The current project was a retrospective, observational, nationwide propensity-matched analysis comparing outcomes of US Veterans 65 years and older who received either of these oral antivirals to US Veterans 65 years and older who did not receive oral antivirals for mild-to-moderate SARS-CoV-2 active infection. RESULTS: The composite primary outcome of admission or death within 30 days of diagnosis was reached less often in those receiving either molnupiravir or nirmatrelvir/ritonavir versus those that received no antiviral (65/1370 [4.75%] vs. 139/1370 [10.2%]; odds ratio 0.44, 95% confidence interval 0.32-0.60, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Service, Oklahoma City Veterans Affairs Health Care System, 921 Northeast 13th Street (119), Oklahoma City, OK 73104, USA. Electronic address: chris.gentry@va.gov.
- PGY1 Pharmacy Resident, Pharmacy Service, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, OK, USA.
- Infectious Diseases, Medical Service, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, OK, USA. Electronic address: Sharanjeet.thind@va.gov.
- Medical Service, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, OK, USA.
- Infectious Diseases, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, OK, USA.
Zitieren
APA
Gentry, C. A., Nguyen, P., Thind, S. K., Kurdgelashvili, G., & Williams, R. J. (2023). Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. Journal of Infection. https://doi.org/10.1016/j.jinf.2023.01.018
Vancouver
Gentry CA, Nguyen P, Thind SK, Kurdgelashvili G, Williams RJ. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. Journal of Infection. 2023. doi:10.1016/j.jinf.2023.01.018
BibTeX
@article{Gentry2023,
author = {Gentry, Chris A and Nguyen, Phoi and Thind, Sharanjeet K and Kurdgelashvili, George and Williams, Riley J},
title = {Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents},
journal = {Journal of Infection},
year = {2023},
doi = {10.1016/j.jinf.2023.01.018}
}
EUVIMED